SPC
TVRD

Slate Path Capital’s Tvardi Therapeutics TVRD Stock Holding History

Slate Path Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Hold
704,118
– – 0.02% 39
2026
Q1 		$2.24M Hold
704,118
– – 0.03% 42
2025
Q4 		$3.03M Hold
704,118
– – 0.04% 49
2025
Q3 		$27.4M Hold
704,118
– – 0.42% 43
2025
Q2 		$16.4M Buy
+704,118
New +$16.6M 0.28% 37

Other funds holding TVRD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Slate Path Capital's TVRD Position: Q2 2026 in Review

Slate Path Capital held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 704,118 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #39.

Slate Path Capital first reported a position in TVRD in Q2 2025 and has held it in 5 quarters since. The position peaked at $27.4M in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Slate Path Capital held 704,118 shares of Tvardi Therapeutics worth $1.34M as of Q2 2026.
  • Slate Path Capital left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up 0.02% of Slate Path Capital's portfolio in Q2 2026, its #39 holding.
  • Slate Path Capital first reported a position in Tvardi Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Slate Path Capital's Tvardi Therapeutics position peaked at $27.4M in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Slate Path Capital's 13F filing for Q2 2026, filed 14 Aug 2026.